Lv1
40 积分 2023-03-21 加入
BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer
1年前
已完结
Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib
1年前
已完结
Structural Mechanisms for Replicating DNA in Eukaryotes
1年前
已完结
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
1年前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
2年前
已完结
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations
2年前
已完结
Cancer-associated mutations in SF3B1 disrupt the interaction between SF3B1 and DDX42
2年前
已完结
Genomic landscape of microsatellite instability in Chinese tumors: a comparison of Chinese and TCGA cohorts
2年前
已完结
皖公网安备34019202002308
